Literature DB >> 16721739

Response to intraarterial induction chemotherapy: a prognostic parameter in oral and oropharyngeal cancer.

Adorján F Kovács1.   

Abstract

BACKGROUND: Patients with head and neck cancer and good pathologic response to neoadjuvant systemic induction chemotherapy have a better prognosis for survival than do those with stable or progressive disease. Thus, induction chemotherapy could theoretically help in stratifying further treatment, but toxicity is much too high. The prognostic implication of superselective intraarterial high-dose cisplatin administered by a femoral approach, which has much less toxicity, is not yet known.
METHODS: One hundred eighty-seven unselected consecutive patients with previously untreated oral and oropharyngeal squamous cell carcinoma received intraarterial high-dose cisplatin for induction and were assessed for response by visual examination and palpation. This treatment was followed by surgery and adjuvant radiation with concomitant systemic chemotherapy. Omission of a modality depended on individual contraindications and not on preselection. The consequence of omissions has been the constitution of several treatment arms. The overall and disease-free survival in relation to clinical local response after intraarterial induction chemotherapy was calculated using the Kaplan-Meier method. Additional analysis excluded bias caused by stages and treatment arms.
RESULTS: Explorative statistics using the log-rank and chi-square tests demonstrated a strong prognostic relevance of response to intraarterial chemotherapy irrespective of stage and treatment.
CONCLUSIONS: Our results are encouraging for prospective randomized studies and molecular genetic investigations with intraarterial chemotherapy.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16721739     DOI: 10.1002/hed.20388

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  2 in total

1.  When is chemotherapy in head and neck squamous cell carcinoma not indicated?

Authors:  Missak Haigentz; Jan B Vermorken; Arlene A Forastiere; June Corry; Jonathan J Beitler; Primož Strojan; Dana M Hartl; Juan P Rodrigo; Carol R Bradford; Alessandra Rinaldo; Robert P Takes; William M Mendenhall; Ashok R Shaha; Gregory T Wolf; Alfio Ferlito
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-02-14       Impact factor: 2.503

2.  Approaching 10 years disease-free survival after isolated thoracic perfusion for advanced stage IV tonsil carcinoma: A case report.

Authors:  Karl R Aigner; Emir Selak; Kornelia Aigner
Journal:  Int J Surg Case Rep       Date:  2020-09-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.